Pharma QC Solutions Designed to Meet GxP Requirements Poster | Sartorius

Detection of Nucleic Acid Traces – A PCR Kit Manufacturer Perspective | Poster

Authors: Lisa Hollstein, Miriam Dormeyer, Robert Hertel, Alexandra Müller Scholz | Last updated: September 2023

Overview

The bio-pharmaceutical industry has seen a significant shift towards personalized cell and gene therapy products in recent years. This shift has brought about new quality control requirements and the development of several rapid microbial detection methods. USP <1071> emphasizes the importance of real-time contamination detection prior to the administration of short-life products. However, the new methods strive to detect the "holy grail" of 1 CFU (colony-forming unit). The question arises, will this ever be possible, or is it even necessary?


  • Document type: Poster
  • Page count: 1
  • Read time: 5 minutes


Complete the Form to Access the Poster

Key Takeaways

In this poster, we will:

  • Walk you through state-of-the-art nucleic acid detection, explaining the critical steps involved.

  • Address key requirements such as the limit of detection and how to handle "false" positives.

  • Highlight the many benefits of this approach.

  • Share our findings from the quantification of the positive control (PC) of our Microsart® ATMP Sterile Release Kit, which sheds light on the borderline between sensitivity and noise.

  • Propose an open discussion on this advanced method and the importance of understanding standards in QC testing and release.

This Resource is Designed for:

  • Lab managers, Scientists, Technicians in the QC within the Cell and Gene Therapy area

Applications Supported:

  • Rapid Sterility Testing (DNA extraction followed by Real-time PCR)

Complete the Form to Access the Poster